Characterization of a monoclonal antibody against human prolactin receptors.
Tamoxifen is the first line of therapy for most human breast cancers. It not only works through the estrogen receptor but also can directly affect the binding of prolactin to its receptor. To define this latter mechanism, the nature of the prolactin receptor needs to be clearly defined. Monoclonal antibody (MAb) B6.2, and IgG1 raised against a membrane-enriched fraction from metastatic human breast cancer cells, was as effective as polyclonal anti-prolactin receptor antibody in inhibiting the binding of prolactin to membranes from human tissue and to T47D human breast cancer cells. Control MAbs, MOPC-2I and the anti-NCA B1.1 MAb, had no effect on binding. Epidermal growth-factor receptors on these same cells were unaffected by B6.2. Prolactin-induced growth of the T47D cells was blocked by addition of B6.2 to the media while the control antibodies were without effect. Specific binding of B6.2 to the cells was completely inhibited by prolactin. Binding of both prolactin and B6.2 was inhibited by growing the T47D cells in the presence of tunicamycin A1 under conditions where protein synthesis was not affected but glycosylation of proteins was. An affinity column of B6.2 was used to purify its antigen from T47D cells. The primary purification product, a M(r) 90,000 protein, specifically bound the lactogenic hormones human prolactin, human growth hormone and ovine prolactin but not the somatogenic hormone, bovine growth hormone and was precipitated by the polyclonal anti-prolactin receptor antibody but not by control MAbs. When tryptic and V8 digests of the B6.2 antigen and purified prolactin receptors were compared, identical electrophoretic profiles were obtained. Mouse 3T3 cells, when stably transfected with the gene for the long form of the human prolactin receptor, reacted with B6.2 and polyclonal anti-prolactin receptor antibody. Parental 3T3 cells, devoid of prolactin receptors, were negative for all antibodies tested. Thus, MAb B6.2 provides a useful tool for further studies on purification and characterization of these receptors from human tissues and may provide new insights into treatment for breast cancer.
Banerjee
R
R
Laboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda, MD 20892.
Ginsburg
E
E
Vonderhaar
B K
BK
D016475:3T3 Cells; D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000378:metabolism / Q000494:pharmacology; D000951:Antigens, Neoplasm / Q000302:isolation & purification; D001943:Breast Neoplasms / Q000737:chemistry* / Q000473:pathology; D002455:Cell Division / Q000187:drug effects; D010450:Endopeptidases / Q000378:metabolism; D000939:Epitopes / Q000276:immunology; D013006:Growth Hormone / Q000378:metabolism; D006801:Humans; D007150:Immunohistochemistry; D007163:Immunosorbent Techniques; D051379:Mice; D011388:Prolactin / Q000378:metabolism / Q000494:pharmacology; D011981:Receptors, Prolactin / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D014162:Transfection; D014407:Tumor Cells, Cultured; D014415:Tunicamycin / Q000494:pharmacology
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D000939:Epitopes; D011981:Receptors, Prolactin; D014415:Tunicamycin; D011388:Prolactin; D013006:Growth Hormone; D010450:Endopeptidases